Novel therapeutic strategies are clearly needed, and the identification of PrP as a receptor for toxic Aβ oligomers provides a tractable therapeutic approach, and indeed one in which the intense recent focus on targeting PrP in prion disease has established a firm experimental foundation (35). This evidence concerns the gene PRNP and prion disease.